ResourceLife Sciences
Characterizing T-cell immune responses against SARS-COV-2 with Ella
14 Oct 2020Immune cell therapy has revolutionized the way we think about treating cancer, but could this type of immunotherapy be beneficial in an infectious disease setting? The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and its associated coronavirus disease 2019 (COVID-19) has certainly presented researchers with an opportunity to evaluate its therapeutic utility.
Related Products
Request Quote for All Products
Ella Automated Immunoassay System
Bio-TechneElla is an automated ELISA platform that fits right on the benchtop of any laboratory. Ella simplifies multiplexing and presents consistent biomarker detection in less than 90 minutes, using only 25 µL of sample, and generating triplicate data, offering more flexibility than other instruments within the immunoassay space.